To reach the next value inflection
LicenseRx asset brief
Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics
Probability of Success
24% · grade C · Medium data confidence
Model PoS 24% (grade C, medium data confidence). Strongest signals: Data maturity, Competitive whitespace. Biggest drag: Translational evidence.
Data maturity (22%)
54
Preclinical; limited public evidence of validation.
IP position (16%)
45
No clear patent status in public data -- treat IP as unpriced until counsel confirms.
Modality feasibility (14%)
66
Biologic/antibody -- solid path but higher CMC burden.
Indication pull (14%)
73
Neurology, Infectious Disease -- active buyer appetite.
Competitive whitespace (12%)
86
Under-served segment; multi-modal differentiation.
Translational evidence (12%)
54
Public evidence mentions: patient.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →